Numerous studies on cosmetic uses of the two major forms of botulinum type A toxin—onabotulinumtoxinA and abobotulinumtoxinA—have been reported, but there is a lack of published, non-industry-funded data regarding efficacy and patient satisfaction with abobotulinumtoxinA.OBJECTIVES
To evaluate the efficacy of and patient satisfaction with abobotulinumtoxinA injections.METHODS
Retrospective, two-phase study of 185 patients treated with abobotulinumtoxinA for dynamic facial rhytid reduction over an 8-month period. Data were gathered using chart review and patient follow-up.RESULTS
The average total amount of abobotulinumtoxinA injected per visit was similar in each phase (93.7 U in phase I, which used a ratio of 2.5 abobotulinumtoxinA units to 1 onabotulinumtoxinA unit, and 99.6 U in phase II, which used a ratio of 3:1). Of patients with a history of onabotulinumtoxinA injections (89.1% in phase I and 91% in phase II), the majority preferred onabotulinumtoxinA. A similar percentage in each group reported overall satisfaction with abobotulinumtoxinA (70.9% in phase I and 68% in phase II).CONCLUSION
Although generally satisfied with abobotulinumtoxinA, when given a choice between abobotulinumtoxinA and onabotulinumtoxinA, the majority of patients favored the latter. This preference remained even after the dilution of abobotulinumtoxinA was decreased.CONCLUSION
While this study and manuscript was not supported in any way by and pharmaceutical company, Dr. Goldman has been or is a consultant for Allergan, Medicis, Mentor, and Merz and has or is conducting clinical studies for Allergan, Medicis, Mentor, and Merz.